Buprenorphine

Introduction Overview

Generic Name

buprenorphine

Brand Name

Belbuca

Dosage Form

buccal film

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Absorption

Buprenorphine administered via Belbuca is absorbed through the buccal mucosa, allowing for direct transmucosal absorption. This route bypasses extensive first-pass metabolism in the liver, enhancing bioavailability compared to oral administration. Typically, the buccal film adheres between the gum and cheek, dissolving over approximately 30 minutes. Absorption can be influenced by mucosal health, presence of saliva, oral pH, and concurrent mucosal lesions such as mouth sores. After complete dissolution, the medicine achieves sufficient plasma concentrations to provide adequate analgesia for moderate to severe chronic pain. Clinical studies indicate a gradual onset of action consistent with transmucosal delivery.

Distribution

Once absorbed, buprenorphine extensively binds to plasma proteins, primarily alpha and beta globulins. It exhibits high lipid solubility, enabling widespread distribution into body tissues including the central nervous system, where it mediates its analgesic effects via opioid receptors. The volume of distribution is relatively large, reflecting extensive tissue uptake and binding. Its strong affinity for mu-opioid receptors contributes to its prolonged pharmacodynamic activity despite plasma clearance. Buprenorphine also crosses the placenta and is secreted into breast milk, necessitating caution in pregnancy and lactation.

Metabolism

Buprenorphine undergoes extensive hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4) enzymes. The main metabolic pathway is N-dealkylation to norbuprenorphine, an active metabolite with limited central opioid activity. Both buprenorphine and its metabolites are subject to phase II metabolism via glucuronidation, facilitating elimination. The partial agonist properties and active metabolites contribute to the drug’s analgesic duration and safety profile. Hepatic impairment can significantly affect metabolic clearance, necessitating cautious dose adjustment and monitoring of liver function during therapy.

Elimination

Elimination of buprenorphine and its metabolites occurs mainly through biliary excretion into feces, with approximately 70% recovered in the feces, and to a lesser extent, renal excretion, accounting for about 30% of elimination. The systemic clearance is relatively slow, aligning with the extended duration of analgesic effect. The plasma half-life of buprenorphine via transmucosal routes ranges from 24 to 37 hours, allowing for twice-daily or once-daily dosing regimens in chronic pain management. Significant hepatic or renal impairment may prolong elimination and increase risk of accumulation.

Dosage Forms

Adults

Belbuca is available as buccal films delivered in multiple dose strengths to allow individualization based on patient opioid tolerance and pain severity. The available dosage strengths include 75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, and 750 mcg buprenorphine per film. Typically, dosing starts at the lowest dose with titration based on analgesic response and tolerability, administered every 12 hours as part of a around-the-clock regimen for chronic pain. Patients must adhere strictly to prescribed doses to minimize risk of respiratory depression and dependence.

Adolescents

Belbuca is not approved for use in patients under 18 years of age. Safety and efficacy have not been established in pediatric or adolescent populations. Use of opioids in this group carries additional risks, including potential for respiratory depression and impact on developing organ systems.

Special Populations

In patients with hepatic impairment, especially moderate to severe dysfunction, dose adjustments or avoidance of Belbuca is recommended due to decreased metabolism and risk of accumulation. Renal impairment has less impact on buprenorphine elimination, but monitoring is advised. The elderly may require careful dose titration considering increased sensitivity to opioids and risk of adverse effects. Due to the risk of neonatal opioid withdrawal syndrome, use during pregnancy must be carefully considered, weighing benefits and risks. Breastfeeding is contraindicated during Belbuca therapy due to drug excretion into breast milk and potential for harm to the infant.

Mechanism Of Action

Buprenorphine, the active ingredient in Belbuca, is a semi-synthetic opioid with partial agonist activity at the mu-opioid receptor (MOR) and antagonist activity at the kappa-opioid receptor (KOR). By binding with high affinity to MORs located in the central nervous system, including brainstem and spinal cord regions responsible for pain perception, buprenorphine modulates neurotransmission resulting in analgesia. The partial agonism produces effective pain relief but with a ceiling effect for respiratory depression, distinguishing it from full opioid agonists such as morphine or oxycodone. The antagonist action at KORs may contribute to reduced dysphoric effects and improved tolerability. Furthermore, buprenorphine interacts with the ORL-1 (opioid receptor-like 1) receptor, modulating pain pathways and possibly influencing mood. This multifaceted receptor activity underpins buprenorphine's analgesic profile, prolonged duration due to slow dissociation from MORs, and lower abuse potential. Clinically, these properties render Belbuca suitable for managing moderate to severe chronic pain requiring around-the-clock opioid therapy, particularly in patients where safety concerns limit the use of full opioid agonists. Comparative studies highlight its efficacy with a potentially more favorable side effect profile regarding respiratory depression and dependence risk. Ongoing research continues to elucidate receptor interactions and implications for pain management and opioid use disorder therapy.

Pharmacological Actions

Partial agonist at mu-opioid receptors producing analgesia
Antagonist activity at kappa-opioid receptors reducing dysphoria
Binding at ORL-1 receptors modulating pain perception
High receptor affinity resulting in prolonged duration of action
Ceiling effect on respiratory depression enhancing safety
Reduction of opioid withdrawal symptoms at appropriate dosing
Central nervous system depression leading to analgesia and sedation
Modulation of neurotransmitter release influencing pain signaling

Therapeutic Clinical Uses

Around-the-clock management of moderate to severe chronic pain not adequately controlled by non-opioid analgesics
Alternative opioid therapy for patients requiring long-term opioid treatment with improved safety profile
Use in patients with opioid tolerance needing sustained analgesia
Treatment of chronic pain conditions where oral opioid formulations are unsuitable or ineffective
Adjunct in multimodal pain management strategies
Management of pain requiring opioid therapy in patients at risk for respiratory depression

Side Or Adverse Effects

Constipation is a common opioid-induced gastrointestinal effect
Nausea and vomiting often observed especially during treatment initiation
Dizziness and headache may occur due to central nervous system effects
Somnolence and drowsiness can impair cognitive functions and reaction times
Increased sweating (hyperhidrosis) reported frequently
Opioid withdrawal symptoms including shivering, increased sweating, runny nose upon abrupt discontinuation
Respiratory depression, potentially severe and life-threatening if misused or combined with CNS depressants
Hypotension and bradycardia in some individuals
Potential for hepatic adverse effects including elevated liver enzymes and rare cases of hepatitis
Oral mucosal irritation or sores due to buccal film application
Risk of addiction, abuse, and misuse leading to overdose and death
Possible serotonin syndrome when combined with serotonergic drugs
Pruritus or rash indicative of allergic reactions
Rare cases of adrenal insufficiency
Withdrawal symptoms in newborns if used during pregnancy

Precautions

Use with caution in patients with respiratory insufficiency or chronic pulmonary disease
Monitor patients for signs of addiction, abuse, and misuse
Adjust dosing or avoid use in moderate to severe hepatic impairment
Avoid use in patients with severe asthma or gastrointestinal obstruction
Regular dental checkups recommended due to buccal film administration
Gradual tapering required to prevent withdrawal symptoms upon discontinuation
Avoid concomitant use with CNS depressants including alcohol due to additive respiratory depression
Monitor serum cortisol and adrenal function in prolonged therapy
Pregnancy risk of neonatal opioid withdrawal syndrome necessitates careful benefit-risk assessment
Use caution in patients with electrolyte imbalances or cardiac conditions such as long QT syndrome
Monitor for serotonin syndrome when combined with serotonergic agents
Avoid use in patients with history of drug addiction or mental illness without careful evaluation
Assess renal function and adjust therapy if necessary
Patient education on safe storage and disposal to prevent misuse

Warnings

Belbuca can cause life-threatening respiratory depression, particularly during initiation or dose escalation
High potential for addiction, abuse, and misuse resulting in overdose and death
Use during pregnancy may produce neonatal opioid withdrawal syndrome requiring specialized care at birth
Fatal respiratory depression risk increases with concomitant use of benzodiazepines, alcohol, or other CNS depressants
Not approved for use in pediatric patients under 18 years of age
Accidental ingestion, especially by children, can be fatal
Avoid abrupt discontinuation to prevent severe withdrawal symptoms
Carefully monitor liver function during treatment; discontinue if significant hepatotoxicity occurs
Monitor cardiac patients due to potential QT prolongation risk
Use caution when prescribing in patients with history of substance use disorder
Patients should avoid operating heavy machinery or driving until they understand the drug's effects
Proper patient education on risk of misuse and safe handling is mandatory
Pregnant or breastfeeding women should avoid use unless potential benefits outweigh risks
Use with caution in elderly or debilitated patients prone to respiratory depression
Advise patients on the risks of drug interactions and to disclose all medications

Contraindications

Known hypersensitivity to buprenorphine or any component of Belbuca
Severe respiratory depression or acute or severe bronchial asthma
Acute or severe gastrointestinal obstruction including paralytic ileus
Hypersensitivity reactions including anaphylaxis to buprenorphine
Use in children under 18 years of age due to safety and efficacy not established
Concomitant use with monoamine oxidase inhibitors (MAOIs) due to increased risk of serotonin syndrome
Situations where opioids are contraindicated such as uncontrolled asthma or severe respiratory compromise
Patients with known or suspected paralytic ileus
Pregnancy unless benefits clearly outweigh risks due to potential neonatal withdrawal
Severe hepatic impairment without close monitoring

Drug Interactions

Additive respiratory depression with benzodiazepines, alcohol, sedative hypnotics, and other CNS depressants
Enhanced CNS depressive effects with muscle relaxants and antipsychotics
Potential serotonin syndrome when combined with serotonergic agents such as SSRIs, SNRIs, triptans, or MAOIs
Metabolism affected by CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) potentially increasing buprenorphine levels
CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce buprenorphine plasma levels and efficacy
Possible increased sedation with antihistamines and antiemetics
Interactions with diuretics and antihypertensives due to potential hypotension
Contraindicated with other opioids or opioid partial agonists/antagonists in certain contexts
Risk of withdrawal symptoms if combined with opioid antagonists like naloxone or naltrexone
Potential interactions with HIV and hepatitis C treatments affecting metabolism
Drugs affecting QT interval may exacerbate cardiac risks when combined
Avoid concomitant use with drugs that impair gastrointestinal motility increasing absorption variability
Beware of interaction with drugs causing electrolyte imbalance which may predispose to arrhythmia
Interactions with certain antibiotics and antifungals that modify CYP activity requires monitoring

Preparations Of The Drug

Buccal films available in dose strengths of 75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, and 750 mcg buprenorphine per film
Films are designed to adhere to the buccal mucosa and dissolve over approximately 30 minutes
Each film is individually packaged in foil sachets for single-dose use
Prescribed for twice-daily administration as part of an around-the-clock analgesic regimen
This dosage form provides an alternative to transdermal patches or sublingual tablets for opioid therapy
No approved formulations for intravenous, intramuscular, or oral tablet use under the brand Belbuca
Additional buprenorphine products include sublingual tablets, extended-release injections, and implantable rods, but are separate from Belbuca
Belbuca is supplied as a thin, flexible film that minimizes taste and facilitates absorption through the buccal mucosa